Switching to subcutaneous zilucoplan from intravenous complement component 5 inhibitors in generalised myasthenia gravis: a phase IIIb, open-label study

Switching to subcutaneous zilucoplan from intravenous complement component 5 inhibitors in generalised myasthenia gravis: a phase IIIb, open-label study

Background: Zilucoplan, a peptide complement component 5 (C5) inhibitor, is self-administered as a subcutaneous (SC) injection, which offers an alternative to intravenous infusion of antibody-based complement C5 inhibitors. Objective: To evaluate subcutaneous zilucoplan in adults with acetylcholine...

Full description

Saved in:
Bibliographic Details
Main Authors: Miriam Freimer, Urvi Desai, Raghav Govindarajan, Min K. Kang, Shaida Khan, Bhupendra Khatri, Todd Levine, Samir Macwan, Perry B. Shieh, Michael D. Weiss, Jos Bloemers, Babak Boroojerdi, Eumorphia Maria Delicha, Andreea Lavrov, Puneet Singh, James F. Howard
Format: Article
Language:English
Published: SAGE Publishing 2025-07-01
Series:Therapeutic Advances in Neurological Disorders
Online Access:https://doi.org/10.1177/17562864251347283
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1177/17562864251347283

Similar Items